» Articles » PMID: 36307542

Combinatorial Gene Targeting in Primary Human Hematopoietic Stem and Progenitor Cells

Overview
Journal Sci Rep
Specialty Science
Date 2022 Oct 28
PMID 36307542
Authors
Affiliations
Soon will be listed here.
Abstract

The CRISPR/Cas9 system offers enormous versatility for functional genomics but many applications have proven to be challenging in primary human cells compared to cell lines or mouse cells. Here, to establish a paradigm for multiplexed gene editing in primary human cord blood-derived hematopoietic stem and progenitor cells (HSPCs), we used co-delivery of lentiviral sgRNA vectors expressing either Enhanced Green Fluorescent Protein (EGFP) or Kusabira Orange (KuO), together with Cas9 mRNA, to simultaneously edit two genetic loci. The fluorescent markers allow for tracking of either single- or double-edited cells, and we could achieve robust double knockout of the cell surface molecules CD45 and CD44 with an efficiency of ~ 70%. As a functional proof of concept, we demonstrate that this system can be used to model gene dependencies for cell survival, by simultaneously targeting the cohesin genes STAG1 and STAG2. Moreover, we show combinatorial effects with potential synergy for HSPC expansion by targeting the Aryl Hydrocarbon Receptor (AHR) in conjunction with members of the CoREST complex. Taken together, our traceable multiplexed CRISPR/Cas9 system enables studies of genetic dependencies and cooperation in primary HSPCs, and has important implications for modelling polygenic diseases, as well as investigation of the underlying mechanisms of gene interactions.

Citing Articles

Enrichment strategies to enhance genome editing.

Mikkelsen N, Bak R J Biomed Sci. 2023; 30(1):51.

PMID: 37393268 PMC: 10315055. DOI: 10.1186/s12929-023-00943-1.

References
1.
Cohen S, Roy J, Lachance S, Delisle J, Marinier A, Busque L . Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2019; 7(2):e134-e145. DOI: 10.1016/S2352-3026(19)30202-9. View

2.
Zimran E, Papa L, Hoffman R . Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic. Blood Rev. 2021; 50:100853. DOI: 10.1016/j.blre.2021.100853. View

3.
Gundry M, Brunetti L, Lin A, Mayle A, Kitano A, Wagner D . Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Rep. 2016; 17(5):1453-1461. PMC: 5087995. DOI: 10.1016/j.celrep.2016.09.092. View

4.
Duncan A, Rattis F, DiMascio L, Congdon K, Pazianos G, Zhao C . Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol. 2005; 6(3):314-22. DOI: 10.1038/ni1164. View

5.
Heckl D, Kowalczyk M, Yudovich D, Belizaire R, Puram R, McConkey M . Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol. 2014; 32(9):941-6. PMC: 4160386. DOI: 10.1038/nbt.2951. View